source
- FDA issues complete response letter rejecting Summit Therapeutics' lung cancer drugThe U.S. Food and Drug Administration released a complete response letter that rejects Summit Therapeutics' lung cancer candidate, providing the agency’s detailed reasons for the decision. The age…
- Merck halts development of BTK inhibitor acquired in $2.7 billion ArQule purchaseMerck announced it is stopping work on nemtabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. The drug was the primary asset that motivated Merck’s 2019 acquisition of ArQule for $2.7 billion.…